Azafaros
Azafaros is a clinical-stage company focused on developing disease-modifying therapeutics to treat rare lysosomal storage disorders. The company is developing nizubaglustat, a potential treatment for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, which is scheduled to enter Phase 3 studies. Azafaros aims to offer new treatment options for patients with severe rare genetic diseases.
Funding Round: Series B
Funding Amount: €132M
Date: 13-May-2025
Investors: Jeito Capital, Forbion Growth, Seroba, Pictet Group, Forbion Ventures, Schroders Capital, BioGeneration Ventures (BGV)
Markets: Biotech, Therapeutics, Health Care
HQ: Leiden, Zuid-Holland, The Netherlands
Founded: 2018
Website: https://www.azafaros.com/
LinkedIn: https://www.linkedin.com/company/azafaros-b-v
Crunchbase: https://www.crunchbase.com/organization/azafaros
Similar Startups
Retro Biosciences
Markets: Biotech, Longevity,...
HQ: Redwood City, California,...
Leave a Comment
Comments
No comments yet.